Retatrutide
Retatrutide activates GIP, GLP-1 and glucagon receptors. Researchers study body-weight, glucose and liver-fat outcomes; community discussions focus on appetite control, gradual dose changes and the lowest amount that feels effective while allowing adequate eating.
Evidence in this guide: Published trials, sponsor results and separately attributed community accounts.
Discovery: triple-receptor activity and early clinical research ↗Phase 1b: pharmacokinetics and once-weekly study dosing ↗Phase 2: obesity trial ↗
Read the Retatrutide guide ↗